Kazia Therapeutics (ADR)
Develops paxalisib and licensed oncology programs for treatment-resistant cancers.
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Shares outstanding 1.62M · Float 1.60M · 98.6% free float
Insiders — filings are in the shares behind the receipt.
This listing is a depositary receipt and the Form 4 positions here are filed in the shares behind it, a different unit from the share count and in a ratio the filings never state, so no insider percentage is shown.
Institutions13F, as of Mar 31, 2026
23 holders · 1.75M shares · 7 new positions · 14 increased · 4 reduced · 6 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Bleichroeder LP | 400.0K | 24.69% | 0 | May 14, 2026 |
| Stonepine Capital Management, LLC | 345.2K | 21.31% | −115.2K | May 14, 2026 |
| Point72 Asset Management, L.P. | 200.0K | 12.35% | 0 | May 15, 2026 |
| Balyasny Asset Management L.P. | 193.1K | 11.92% | +193.1Knew | May 15, 2026 |
| Flputnam Investment Management Co | 142.5K | 8.80% | +142.5Knew | May 5, 2026 |
| Velan Capital Investment Management LP | 135.3K | 8.35% | −164.7K | May 15, 2026 |
| Dauntless Investment Group, LLC | 79.8K | 4.93% | +79.8K | May 14, 2026 |
| Sequoia Financial Advisors, LLC | 60.0K | 3.70% | +60.0Knew | Apr 30, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Chernett Jorey | 18.50% | 2.11M | 13G | May 27, 2026 ↗ |
| Lynwood Capital Management Inc. | 5.40% | 13G | Jan 23, 2026 ↗ | |
| Ikarian Capital, LLC | 5.10% | 580.8K | 13G | Feb 17, 2026 ↗ |
InsidersForm 4
No current Form 4 position on record.
1 ten-percent owner holds 6.8K shares by Form 4, outside the officers-and-directors figure above · 2 positions are filed in the unlisted share unit (80.3K shares), which no share count here divides
Latest trades
No open-market trades in the last 12 months.
CongressHouse and Senate disclosures
Not reported.